Levonorgestrel

Structure

CASRN

797-63-7

Notes

An active metabolite of norelgestromin and a secondary metabolite of norgestimate.

References

  1. Thomas L. Lemke; David A. Williams; Victoria F. Roche; S. William Zito (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. p. 1403. ISBN 978-1-60913-345-0.
  2. (View all citations for this reference)
  3. Hammond, G. L.; Abrams, L. S.; Creasy, G. W.; Natarajan, J.; Allen, J. G.; Siiteri, P. K. Serum Distribution of the Major Metabolites of Norgestimate in Relation to Its Pharmacological Properties. Contraception 2003, 67 (2), 93–99. (View all citations for this reference)
  4. WHO International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 91: Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy. 2007, Lyon, France. (View all citations for this reference)
  5. Madden, S.; Back, D. J. Metabolism of Norgestimate by Human Gastrointestinal Mucosa and Liver Microsomes in Vitro. J. Steroid Biochem. Mol. Biol. 1991, 38 (4), 497–503. (View all citations for this reference)
  6. Wong, F. A.; Edom, R. W.; Duda, M.; Tischio, J. P.; Huang, M.; Juzwin, S.; Tegegne, G. Determination of Norgestimate and Its Metabolites in Human Serum Using High-Performance Liquid Chromatography with Tandem Mass Spectrometric Detection. J. Chromatogr. B Biomed. Sci. Appl. 1999, 734 (2), 247–256. (View all citations for this reference)
  7. MonoNessa: Norgestimate and Ethinyl Estradiol. DailyMed, a National Library of Medicines online database. (View all citations for this reference)
  8. White, T.; Özel, B.; Jain, J. K.; Stanczyk, F. Z. Effects of Transdermal and Oral Contraceptives on Estrogen-Sensitive Hepatic Proteins. Contraception 2006, 74 (4), 293–296.
  9. (View all citations for this reference)
  10. FDA Ortho Evra Information (View all citations for this reference)